Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944088 | 0.94 | NPC1 (0.53) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944098 | 0.90 | PKM (0.60) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944095 | 0.88 | RARA (0.52) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944079 | 0.87 | KMT2A (0.54) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944102 | 0.85 | NPC1 (0.48) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944138 | 0.85 | TAS1R3 (0.57) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL1457759 | 0.84 | TAS1R3 (0.64) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944099 | 0.84 | RAB9A (0.50) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944084 | 0.83 | RAB9A (0.51) | NPC1RAB9AKMT2APKMMEN1 | |
| SCHEMBL9944089 | 0.82 | PKM (0.65) | NPC1RAB9AKMT2APKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | NPC1 277/4885RAB9A 271/4885KMT2A 1418/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | NPC1 277/4885RAB9A 271/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.